ICAD (ICAD) Aandeel Koers
ICAD Koers
De omzet van ICAD is de afgelopen 19 jaar met 0,0% per jaar gedaald tot 19,61 Miljoen USD. Bij ICAD is de nettowinstmarge met -28,6% ten opzichte van -59,3% enkele jaren geleden gestegen. Het consensus-koersdoel voor ICAD op 12 maanden bedraagt 3,57 USD, circa 7,8% onder de huidige koers. Van de 10 analisten geven 6 het aandeel een koopadvies — per saldo een Kopen-consensus.
ICAD aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
ICAD bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over ICAD
ICAD Inc's business model primarily focuses on providing innovative medical solutions to enhance cancer detection and therapy planning. As a leading provider of advanced imaging and radiation therapy technologies, ICAD aims to deliver state-of-the-art solutions that enable healthcare professionals to accurately diagnose and treat patients. Their expertise lies in developing and commercializing computer-aided detection (CAD) and workflow solutions for medical imaging in specialties such as breast, lung, and colon health. With a mission to improve patient outcomes and healthcare efficiency, ICAD Inc strives to revolutionize cancer care through their cutting-edge technologies.
ICAD Inc is primarily active in the healthcare and technology industries.
The main competitors of ICAD Inc in the market include companies like Varian Medical Systems, Elekta AB, and Accuray Incorporated.
ICAD Inc is a renowned company that specializes in advanced image analysis and cancer detection technologies. With a rich history spanning several decades, ICAD Inc was founded in 1984 as a research and development firm focusing on computer-aided detection (CAD) tools for mammography. Over the years, the company expanded its portfolio, offering innovative solutions for various cancer types, including lung, colon, and prostate. With a commitment to improving patient outcomes, ICAD Inc remains at the forefront of cutting-edge medical advancements. Leveraging its expertise in artificial intelligence and machine learning, ICAD Inc continues to deliver state-of-the-art solutions for early cancer detection, contributing to the advancement of medical diagnostics.
ICAD Inc has achieved several significant milestones over the years. Some of these include the development of innovative and leading-edge solutions for advanced imaging in the healthcare industry. The company has also successfully launched its renowned ProFound AI platform, which provides invaluable assistance to radiologists in the early detection of breast cancer. Furthermore, ICAD Inc has consistently focused on expanding its global presence by forging strategic partnerships and collaborations with industry leaders. With a commitment to continuous research and development, ICAD Inc continues to revolutionize the field of medical imaging, ensuring improved patient outcomes and enhanced clinical workflows.
ICAD Inc is primarily present in the United States, with headquarters located in Nashua, New Hampshire. As a leading provider of advanced image analysis technology solutions for the healthcare industry, ICAD Inc serves customers across the United States and also has a strong presence in Europe, Asia, and other regions around the globe. With its innovative solutions and commitment to improving patient outcomes, ICAD Inc continues to expand its reach in healthcare markets worldwide.
ICAD Inc represents values of innovation, collaboration, and dedication to advanced medical imaging technology. With a strong corporate philosophy focused on enhancing patient care and improving clinical outcomes, ICAD Inc continually develops cutting-edge solutions for early cancer detection and radiation therapy. By combining their expertise in artificial intelligence and image analysis, ICAD Inc enables healthcare professionals to make more accurate diagnoses and tailor personalized treatment plans. With a commitment to continuous improvement and providing superior healthcare solutions, ICAD Inc has established itself as a trusted leader in the industry.
Analisten hanteren momenteel een gemiddeld koersdoel van 3,57 USD voor het aandeel ICAD (mediaan: 3,57 USD), oftewel -7,8 % ten opzichte van de laatste koers. De consensus is gebaseerd op 10 analistenratings.
10 analisten beoordelen het aandeel ICAD momenteel: 6 adviseren kopen, 4 houden en 0 verkopen. Voor 2026 verwachten analisten dat ICAD een omzet van 22,33 Miljoen USD en winst per aandeel van -0,12 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel ICAD op 3,51 EUR (3,87 USD).
Het aandeel ICAD (ICAD) is genoteerd aan 1 beurzen, waaronder: NASDAQ (ICAD).
ICAD Inc is a US-based company that has been operating in the field of medical imaging since 1984. The company's business model focuses on the development and manufacturing of advanced imaging products. ICAD offers two main product lines: iCADx and ProFound AI. iCADx is a specialized group of diagnostic products used in image analysis in radiology and brachytherapy. ProFound AI is a groundbreaking software platform specifically designed for the interpretation of digital breast tomosynthesis (DBT). The two product lines from ICAD allow doctors to obtain more accurate and faster diagnostic results. The iCADx brand offers a range of products for the treatment of breast, prostate, lung, bone, and other types of cancer. The range also includes equipment for brachytherapy, a form of radiation therapy where a radiation source is directly inserted into the body. ProFound AI is an artificial intelligence (AI)-based software platform specifically designed for breast imaging. The system uses state-of-the-art algorithms and image analysis functions to assist the doctor in the early detection and diagnosis of breast cancer. In addition, ICAD also offers professional services such as training, customer support, and technical support. These services are aimed at ensuring that the products are used optimally and achieve the highest quality of imaging and diagnosis. ICAD also operates in the research and development field. The company continuously invests in research and development to improve and further develop its products, in order to provide medical users with the best possible diagnostics. The company also actively collaborates with leading medical institutions, research organizations, and other companies to drive collaborative projects and innovation in the field of medical imaging. In conclusion, it can be said that ICAD's business model is based on state-of-the-art medical imaging technology that improves diagnosis in medical practice. ICAD aims to drive further growth and expansion of the company by constantly improving its technologies and introducing innovative products to the market.
De verwachte omzet van ICAD bedraagt 22,33 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van ICAD bedraagt -3,03 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van ICAD bedraagt momenteel -33,65. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het ICAD-aandeel in te schatten.
De koers-omzetverhouding (P/S) van ICAD bedraagt momenteel 4,57. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het ICAD-aandeel.
De Eulerpool Kwaliteitsscore voor ICAD is 0/10.
De ISIN van ICAD is US44934S2068. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van ICAD is A1J20J. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van ICAD is ICAD. Onder dit beurstickersymbool wordt het ICAD-aandeel op de beurs verhandeld.
ICAD aandeel
ICAD Peer Group
ICAD Ticker
ICAD FIGI
Alle fundamentals en diepgaande analyse van ICAD
Onze aandelenanalyse van het ICAD-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van ICAD. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: